| Literature DB >> 34774030 |
Wen Li1,2,3, Xiaobin Wang1,2,3, Xianbin Zhang1,3,4, Peng Gong1,3,4, Degang Ding5, Ning Wang5, Zhifeng Wang6.
Abstract
BACKGROUND: The high drug resistance and metabolic reprogramming of clear cell renal cell carcinoma (ccRCC) are considered responsible for poor prognosis. In-depth research at multiple levels is urgently warranted to illustrate the lipid composition, distribution, and metabolic pathways of clinical ccRCC specimens.Entities:
Keywords: Clear cell renal cell carcinoma; Differentially expressed lipids; Lipid biomarker; Lipid metabolite; Lipid quantification; Lipidomics; Lipids; UPLC-MS/MS
Mesh:
Substances:
Year: 2021 PMID: 34774030 PMCID: PMC8590225 DOI: 10.1186/s12944-021-01572-z
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Clinical information of 10 patients
| Characteristics | Value N (%) or Mean ± SD |
|---|---|
| Age | 54.00 ± 10.40 |
| Sex (Male) | 10 (80%) |
| T1/T2 States | 7 / 3 |
| Tumor diameter (cm) | 5.03 ± 2.40 |
| Hypertension | 10 (10%) |
| Cigarette smoking | 10 (10%) |
| ALT, U/L | 20.92 ± 14.40 |
| AST, U/L | 21.58 ± 7.49 |
| TP, g/L | 64.07 ± 10.10 |
| TBIL, μmol/L | 10.60 ± 6.08 |
| ALP, U/L | 72.37 ± 22.34 |
| GGT, U/L | 26.01 ± 13.68 |
| TBA, μmol/L | 1.94 ± 1.21 |
| CHE, KU/L | 7.94 ± 2.85 |
| LDH, U/L | 215.38 ± 42.83 |
| GLDH-D, U/L | 3.89 ± 1.75 |
| NEFA-D, mmol/L | 0.28 ± 0.17 |
| CHOL, mmol/L | 5.10 ± 0.64 |
| TG, mmol/L | 1.83 ± 0.23 |
| HDL-C, mmol/L | 1.11 ± 0.13 |
| LDL-C, mmol/L | 3.36 ± 0.53 |
| APO-A1, g/L | 1.12 ± 0.23 |
| APOB100, g/L | 1.07 ± 0.20 |
| LPa, mg/dL | 4.40 ± 1.98 |
| UREA, mmol/L | 5.78 ± 1.49 |
| CREA, μmol/L | 103.50 ± 39.03 |
| UA, μmol/L | 339.33 ± 74.27 |
| GLU, mmol/L | 5.78 ± 1.18 |
ALT: alanine aminotransferase; AST: aspartate aminotransferase; TP: total protein; TBIL: total bilirubin; ALP: alkaline phosphatase; GGT: glutamyl transferase; TBA: total bile acid; CHE: cholinesterase; LDH: lactate dehydrogenase; GLDH-D: glutamate dehydrogenase; NEFA-D: non-estesterified fatty acid; CHOL: cholesterol; TG: triglycerides; HDL-C: high density lipoprotein; LDL-C: low density lipoprotein; APO-A1: Apolipoprotein-A1; APOB100: Apolipoprotein B100; LPa: lipoprotein; CREA: Creatinine; UA: Uric acid; GLU: Glucose
The internal standard used in this study
| Glass | Abbreviations | internal standards | Concentration (nmol/mL, μM) |
|---|---|---|---|
| Free fatty acid | FFA | FFA(18:2)-d11 | 0.2 |
| Acylcarnitine | CAR | CAR(16:0)-d3 | 0.2 |
| Eicosanoids | Eicosanoid | 5S-HETE-d8 | 0.04 |
| Cholesterol | Cho | Cho-d7 | 5 |
| Cholesteryl ester | CE | CE(18:1)-d7 | 2 |
| Bile Acid | BA | GCDCA-d4 | 0.04 |
| Sphingosine | SPH | SPH(18:1)-d7 | 0.04 |
| Ceramide | Cer | Cer(d18:1(d7)/18:0) | 0.2 |
| Ceramide 1-phosphates | CerP | CerP(d18:1/8:0) | 0.4 |
| Hexosylceramide | HexCer | HexCer(d18:1(d5)/18:0) | 0.4 |
| Sphingomyelin | SM | SM(d18:1(d9)/15:0) | 0.2 |
| Diacylglycerol | DG | DG(17:0/17:0)_d5 | 0.2 |
| Triacylglycerol | TG | TG(17:0/17:1/17:0)_d5 | 0.2 |
| Lysophophatidylcholine | LPC | LPC(16:0)-d31 | 0.2 |
| alkyl-Lysophophatidylcholine | LPC-O | LPC(16:0)-d31 | 0.2 |
| Lysophosphatidylethanolamine | LPE | LPE(14:0) | 0.2 |
| alkenyl-Lysophosphatidylethanolamine | LPE-P | LPE(14:0) | 0.2 |
| Lysophosphatidylglycerol | LPG | LPG(14:0) | 0.2 |
| Lysophosphatidylinositol | LPI | LPI(17:1) | 0.2 |
| Lysophosphatidylserine | LPS | LPS(17:1) | 0.2 |
| Phosphatidylcholine | PC | PC(16:0(d31)/18:1) | 0.2 |
| alkyl-glycerophosphocholines | PC-O | PC(16:0(d31)/18:1) | 0.2 |
| Phosphatidylethanolamine | PE | PE(16:0(d31)/18:1) | 0.2 |
| alkenyl-glycerophosphoethanolamines | PE-P | PE(16:0(d31)/18:1) | 0.2 |
| Phosphatidylglycerol | PG | PG(16:0(d31)/18:1) | 0.4 |
| Phosphatidylinositol | PI | PI(16:0(d31)/18:1) | 0.2 |
| Phosphatidylserine | PS | PS(16:0(d31)/18:1) | 0.4 |
| Coenzyme Q | CoQ | CoQ10-d9 | 0.4 |
Standard curve linear equation
| Class | Equation | r | LLOQ | ULOQ |
|---|---|---|---|---|
| BA | y = 5.89032 x + 0.00349 | 0.99952 | 0.001 | 1 |
| CAR | y = 10.63664 x - 9.00378e-4 | 0.99178 | 0.005 | 5 |
| CE | y = 4.15246 x - 0.00124 | 0.99310 | 0.01 | 5 |
| Cer | y = 2.90771 x + 0.00126 | 0.99628 | 0.002 | 2 |
| CerP | y = 0.14978 x + 7.83392e-5 | 0.99815 | 0.005 | 2 |
| Cho | y = 4.27736 x + 0.02240 | 0.99768 | 0.005 | 5 |
| CoQ | y = 3.64824 x + 1.73992 | 0.99749 | 0.002 | 2 |
| DG | y = 7.54751 x + 0.04692 | 0.99412 | 0.002 | 2 |
| Eicosanoid | y = 61.65750 x + 0.08742 | 0.99661 | 0.001 | 1 |
| FFA | y = 22.05858 x - 0.21591 | 0.99297 | 0.02 | 10 |
| HexCer | y = 1.40675 x - 2.86002e-5 | 0.99152 | 0.002 | 2 |
| LPC | y = 2.87925 x - 0.00565 | 0.99009 | 0.01 | 5 |
| LPC-O | y = 2.87925 x - 0.00565 | 0.99009 | 0.01 | 5 |
| LPE | y = 0.43538 x - 0.00138 | 0.99562 | 0.02 | 5 |
| LPE-P | y = 0.43538 x - 0.00138 | 0.99562 | 0.02 | 5 |
| LPG | y = 0.62714 x - 1.52689e-5 | 0.99848 | 0.005 | 2 |
| LPI | y = 0.06717 x + 0.00722 | 0.99669 | 0.002 | 2 |
| LPS | y = 0.10692 x + 2.42176e-5 | 0.99127 | 0.01 | 2 |
| PC | y = 1.39542 x - 6.09826e-4 | 0.99651 | 0.002 | 10 |
| PC-O | y = 1.39542 x - 6.09826e-4 | 0.99651 | 0.002 | 10 |
| PE | y = 14.19927 x - 0.02853 | 0.99327 | 0.01 | 5 |
| PE-P | y = 1.01408 x - 0.00815 | 0.99613 | 0.02 | 5 |
| PG | y = 6.97289 x + 0.01424 | 0.99033 | 0.01 | 10 |
| PI | y = 3.05988 x - 0.15491 | 0.99717 | 0.02 | 5 |
| PS | y = 6.52668 x - 0.37092 | 0.99437 | 0.01 | 10 |
| SM | y = 0.68841 x - 5.22709e-4 | 0.99110 | 0.002 | 10 |
| SPH | y = 1.80406 x + 4.28477e-4 | 0.99513 | 0.005 | 2 |
| TG | y = 1.33356 x + 5.11722e-4 | 0.99125 | 0.005 | 10 |
Class: lipid classification; Equation: linear equation; r: the correlation coefficient; LLOQ (nmol/mL): lower limit of quantification; ULOQ (nmol/mL): upper limit of quantification
The specific lipid specie that was used to generate the calibration curve
| Class | Lipid name | CAS number | Supplier | Article number |
|---|---|---|---|---|
| FFA | FA(18:2) | 60–33-3 | sigma-Aldrich | L1376 |
| CAR | CAR(16:0) | 2364-67-2 | Supelco | 91,503 |
| Eicosanoid | 5S-HETE | 73,307–52-5 | cayman | 34,210 |
| Cho | cholesterol | 57–88-5 | sigma-Aldrich | C3045 |
| CE | CE(18:2) | 604–33-1 | sigma-Aldrich | C0289 |
| BA | Glycochenodeoxycholic acid | 16,564–43-5 | sigma-Aldrich | G0759 |
| SPH | SPH(18:1) | 213–78-4 | Avanti | |
| Cer | Cer(d18:1/17:0) | 67,492–21-4 | Avanti | 860517P |
| CerP | CerP(d18:1/16:0) | 2,146,303–22-9 | Avanti | 860533P |
| HexCer | HexCer(d18:1/16:0) | 2,260,795–77-3 | Cayman | 26,009 |
| SM | SM(d18:1/17:0) | 121,999–64-2 | Avanti | 860585P |
| DG | DG(17:0/17:0) | 98,896–81-2 | Cayman | 26,942 |
| TG | TG(17:0/17:0/17:0) | 2438-40-6 | sigma-Aldrich | T2151 |
| LPC | LPC(17:0) | 50,930–23-9 | Avanti | 855676P |
| LPC-O | LPC(17:0) | 50,930–23-9 | Avanti | 855676P |
| LPE | LPE(18:0) | 69,747–55-3 | Avanti | 856715P |
| LPE-P | LPE(18:0) | 69,747–55-3 | Avanti | 856715P |
| LPG | LPG(18:0) | 326,495–23-2 | Avanti | 858214P |
| LPI | LPI(18:1) | 799,268–53–4 | Avanti | 850149P |
| LPS | LPS(18:1) | 326,589–90-6 | Avanti | 858143P |
| PC | PC(17:0/17:0) | 70,897–27-7 | Avanti | 850360P |
| PC-O | PC(17:0/17:0) | 70,897–27-7 | Avanti | 850360P |
| PE | PE(17:0/17:0) | 140,219–78-9 | Avanti | 830756P |
| PE-P | PE(P-18:0/18:1) | 144,371–68-6 | Avanti | 852758P |
| PG | PG(17:0/17:0) | 799,268–52-3 | Avanti | 830456P |
| PI | PS(16:0/18:1) | 321,863–21-2 | Avanti | 840034P |
| PS | PI(16:0/18:1) | 50,730–13-7 | Avanti | 850142P |
| CoQ | CoQ10 | 303–98-0 | Supelco | 7386 |
Fig. 1Lipid identification. A The type and number of identified lipids. B The total content of lipid molecules. C The PCA analysis on tumor and normal samples. D OPLS-DA score chart. The abscissa represents the predicted principal component and abscissa direction indicates the gap between groups. The ordinate represents the orthogonal principal component and the ordinate direction indicates the gap within the group. E The verification diagram OPLS-DA model. R2X = 0.442, R2Y = 0.862, Q2 = 0.73, P < 0.005. F S-plot of OPLS-DA model. The abscissa represents the covariance between the principal component and the lipid, and the ordinate represents the correlation coefficient between the principal component and the lipid. The red points indicate that the VIP value of these lipids is greater than or equal to 1, and the green points indicate that the VIP value of these lipids is less than 1
Fig. 2Changes in lipid subclass content. A The up- and down-regulated lipid subtypes between groups. B Dynamic distribution of lipid content. Each point represents a lipid molecule. The ordinate represents the corresponding content of each lipid molecule, and the lipid molecules with the lowest and highest content are marked
Fig. 3The carbon chain length analysis. The content of lipid compounds corresponding to different carbon chain lengths were listed in each group
Fig. 4The chain unsaturation analysis. The content of lipid compounds corresponding to different carbon chain saturations in each group were listed
Fig. 5Differentially expressed lipids. A Bar chart of differentially expressed lipids. FC: Fold change. B The top 20 lipids ranked by VIP value of differentially expressed lipids. C The volcano map of differentially expressed lipids. Each point in the volcano map represents a lipid. Significantly up-regulated lipids are represented by red dots, and significantly down-regulated lipids are represented by green dots. The size of the dot represents the VIP value. D Correlation analysis on the significantly different lipids. Different colors represent the level of Pearson’s correlation coefficient